Boehringer In­gel­heim once again turns to RNAi for new MASH ther­a­pies

Boehringer In­gel­heim is part­ner­ing with Chi­na-based biotech Suzhou Ri­bo Life Sci­ence and its Swe­den-based unit Ri­bo­cure Phar­ma­ceu­ti­cals to de­vel­op siR­NA ther­a­pies for meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH), in a deal po­ten­tial­ly worth $2 bil­lion in biobucks.

The biotech will re­ceive an undis­closed up­front pay­ment, with fur­ther pay­outs if cer­tain clin­i­cal, reg­u­la­to­ry and com­mer­cial mile­stones are reached, as well as tiered roy­al­ties, per a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER